Leukemia, Lymphocytic, Chronic, B-Cell

Showing NaN - NaN of 7

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell Trial in Worldwide (JNJ-75348780)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Birmingham, Alabama
  • +43 more
Jan 27, 2023

Non-Hodgkin's B-cell Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Leukemia Trial in Worldwide (MT-3724

Terminated
  • Non-Hodgkin's B-cell Lymphoma
  • +5 more
  • MT-3724 Phase 1
  • MT-3724 Phase 2
  • Tucson, Arizona
  • +40 more
Jul 18, 2022

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma Trial in Worldwide (BMS-986403, Fludarabine, Cyclophosphamide)

Recruiting
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Lymphoma
  • Birmingham, Alabama
  • +24 more
Jul 6, 2022

Leukemia, Lymphocytic, Chronic, B-Cell Trial in Worldwide (CC-122, Ibrutinib, Obinutuzumab)

Completed
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • La Jolla, California
  • +23 more
Aug 20, 2021

Leukemia, Lymphocytic, Chronic, B-Cell Trial in Spain (Cyclophosphamide, Fludarabine, Rituximab)

Completed
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Vitoria, Alava, Spain
  • +32 more
Jul 27, 2018

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular Trial in Worldwide (Part 1 (Dose

Terminated
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • +4 more
  • Part 1 (Dose Escalation): Duvortuxizumab
  • Part 2 (Dose Expansion): Duvortuxizumab
  • Detroit, Michigan
  • +19 more
Dec 19, 2018

Haematology Score asTool for Predicting Tolerance to Treatment

Completed
  • Myelodysplastic Syndromes
  • +3 more
    • Oviedo, Asturias, Spain
    • +14 more
    Jul 24, 2017